

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application No.: 10/826,303
Attorney Docket No.: Q81147

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-14. (canceled).

15. (currently amended): A method for suppressing an allergy comprising administering a pharmacologically effective amount of an IgE antibody inhibitor containing glucomannan to a patient in need thereof,

wherein the glucomannan is in the form of refined *konjak* flour,

the glucomannan is easily soluble in water, ~~and~~

the glucomannan is a pulverized product with an average particle diameter of 100 μm or less, and

the glucomannan has a dietary fiber content of 95% or more.

16. (canceled).

17. (previously presented): A method for suppressing an allergy as described in claim 15, wherein the glucomannan has a weight average molecular weight of 1,000,000 or more, and a period of time until its 1% aqueous solution reaches the viscosity peak at room temperature is within 30 minutes.

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application No.: 10/826,303
Attorney Docket No.: Q81147

18. (previously presented): A method for suppressing an allergy as described in claim 15, wherein the IgE antibody inhibitor is in the form of a powder, capsule, tablet, pill or granule.

19. (currently amended): A method for suppressing an allergy comprising ingesting a food containing a pharmacologically effective amount of an IgE antibody inhibitor containing glucomannan,

wherein the glucomannan is in the form of refined *konjak* flour,

the glucomannan is easily soluble in water, ~~and~~

the glucomannan is a pulverized product with an average particle diameter of 100 μm or less, and

the glucomannan has a dietary fiber content of 95% or more.

20. (canceled).

21. (previously presented): A method for suppressing an allergy as described in claim 19, wherein the glucomannan has a weight average molecular weight of 1,000,000 or more, and a period of time until its 1% aqueous solution reaches the viscosity peak at room temperature is within 30 minutes.

AMENDMENT UNDER 37 C.F.R. § 1.111

U.S. Application No.: 10/826,303

Attorney Docket No.: Q81147

22. (previously presented): A method for suppressing an allergy as described in claim 22, wherein the IgE antibody inhibitory food on the form of a powder, capsule, tablet, pill or granule.